Kennedy Peptide Reclassification: What Changed and What It Means

What we can verify

Here is the documented record on peptides and 503A compounding, drawn from FDA's own publications and the Federal Register.

FDA maintains a statutory 503A Bulks List and a separate set of interim-policy categories. These are different things, and vendors conflate them constantly. The 503A Bulks List is established by rulemaking. The "Category 1 / 2 / 3" buckets come from FDA's interim policy on compounding with bulk drug substances and describe enforcement discretion, not statutory status.^[1][3]

FDA continues to publish safety-risk findings for a number of nominated peptide bulk substances.^[2]

On April 16, 2026, FDA published a Federal Register notice convening a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider seven peptide bulk drug substances for the 503A Bulks List, and opened public docket FDA-2025-N-6895.^[4]

That meeting happened. The committee recommended six of the seven — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the list. Emideltide (DSIP) was voted down.^[5]

FDA's own review team had recommended against all seven. Its slides state, for BPC-157: "FDA is proposing that BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List."^[6]

FDA has taken no action since. As of August 15, 2026 there is no proposed rule, no Federal Register document, and no change to any bulks list. None of those six peptides is legal to compound today.

---

Why we are not repeating the reclassification story

A few things we specifically could not confirm, and therefore will not publish:

• Any HHS or Secretary-level statement in the relevant windows that roughly 14 of 19 Category 2 peptides would be returned to Category 1.
• That FDA removed twelve peptides from Category 2 on a specific date in April 2026. FDA's own bulk-substance pages carry "content current as of" stamps, and those stamps do not support an in-window list change.^[1][2]
• That FDA signalled it would "soon remove" the peptides under review from any restricted list. The April 2026 Federal Register notice is a meeting notice; it does not say that.^[4]

We are not saying these things definitely did not happen. We are saying we could not find a primary source for them, and a peptide encyclopedia that cites press releases it cannot open is not worth reading. If FDA or HHS publishes documentation, we will update this page.

---

What this means for you

The practical status has not changed. BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and DSIP are not on the 503A Bulks List. A licensed compounding pharmacy cannot legally prepare them from bulk today.

Watch the Federal Register, not press coverage. The only thing that will change the legal status of these peptides is a proposed rule followed by a final rule. Both appear in the Federal Register. Nothing else — not an advisory vote, not a press statement, not a vendor's blog post — has that effect.

Be skeptical of "peptides are legal again" marketing. The four steps matter: committee recommended is not FDA proposed, which is not FDA finalized, which is not legal to compound. Sellers have a commercial reason to blur them.

For the full record of the July meeting, see our July 2026 PCAC hub. For source-checked status on every peptide we track, see the legal status tracker.

---

References

1. [1]

   U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” FDA.gov. 2026. LinkRegulatory document

   FDA's page defining the 503A Bulks List and the interim-policy categories. Checked August 15, 2026; FDA's own 'content current as of' stamp was May 14, 2026.

2. [2]

   U.S. Food and Drug Administration. “Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding.” FDA.gov. 2026. LinkRegulatory document

   FDA's enumeration of nominated bulk substances it has identified as presenting significant safety risks. Checked August 15, 2026; FDA-stamped current as of April 22, 2026.

3. [3]

   U.S. Food and Drug Administration. “Compounding Laws and Policies: Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.” FDA.gov. 2026. LinkRegulatory guidance
4. [4]

   U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Federal Register. 2026. LinkFederal Register notice

   FR Doc. 2026-07361, published April 16, 2026. Establishes the July 23-24, 2026 PCAC meeting and public docket FDA-2025-N-6895.

5. [5]

   U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” FDA.gov. 2026. LinkRegulatory document
6. [6]

   U.S. Food and Drug Administration. “July 23, 2026 PCAC Meeting — FDA Presentations.” FDA.gov. 2026. LinkRegulatory document

   FDA's own slide deck, in which its review team proposes that none of the seven peptides be added to the 503A Bulks List.

---

---

Related content

Guide

The July 2026 PCAC Peptide Vote

What the advisory committee actually decided, what FDA's reviewers argued, and what has to happen next.

Tool

Peptide Legal Status Tracker

Source-checked status for every peptide we track, updated August 15, 2026.

News

Does This Mean BPC-157 Is Legal Now?

The precise answer to the question the July vote made everyone ask.

News

FDA Peptide Categories Explained

How the interim-policy categories differ from the statutory 503A Bulks List.

Guide

Our Methodology

How we grade evidence, what we cite, and what we do when a source does not hold up.

---